Novavax (NVAX): Too Soon To Evaluate US Vaccination Rates - Bloomberg
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 9.99 -1.02 (9.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.01 | 52 Week High | $9.23 | |||
| Open | $10.79 | 52 Week Low | $1.16 | |||
| Day High | $10.87 | P/E | N/A | |||
| Day Low | $9.56 | EPS | $-0.30 | |||
| Volume | 12,238,798 | |||||
